Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (8.046.250 €): Personalisierte pharmakometabolomische Optimierung der Behandlung von Bluthochdruck Hor 16.12.2022 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Personalisierte pharmakometabolomische Optimierung der Behandlung von Bluthochdruck
Hypertension, or high blood pressure (BP), is a serious medical condition, and the single biggest contributor to circulatory diseases which continue to dominate as the leading cause of death and morbidity across the EU. It accounts for almost 10 percent of all healthcare-related costs. Systolic hypertension leads to a broad variety of diseases with an immense impact on both patients and healthcare systems. HYPERMARKER will unleash the potential of pharmacometabolomics to provide a ‘smart’ prescription of antihypertensive therapy. Well-phenotyped cohorts from eleven European countries will provide metabolomic profiles and blood samples for pharmacometabolomic assessments to identify predictors of treatment response in hypertension using advanced AI and deep learning methods. Prediction models for individual treatment responses to antihypertensive medication will be clinically validated and refined through an innovative RCT across 4 sites in Europe. The result is a clinical decision support tool that will give clinicians the ability to make an informed selection of whether the patient they are treating will best respond to the use of angiotensin inhibition, calcium antagonists, beta-blockers, or a range of other existing drugs with evidence-based for BP control. To ensure sustainability, the project will also develop a framework for the uptake of this tool in routine care for patients with hypertension across Europe and beyond. HYPERMARKER will be implemented by a group of world-class scientists and clinicians from a diversity of disciplines who have collaborated multiple times and have a track record of leading key national and EU-funded initiatives to deliver high-impact results.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| London School of Economics and Political Science | ? |
| Collaborate Project Management GmbH | 250.000 € |
| Euretos B.V. | 38.000 € |
| European Heart Network Aisbl | 156.250 € |
| Fundacion para La Investigacion del Hospital Clinico de La Comunitat Valenciana, Fundacion Incliva | 325.000 € |
| Roche Diagnostics Nederland B.V. | 18.750,00 € |
| Stichting Amsterdam UMC | 97.500 € |
| Universitaetsklinikum Hamburg-Eppendorf | 915.000 € |
| Universitair Medisch Centrum Utrecht | 2.733.750 € |
| Universiteit Leiden | 2.750.500 € |
| Universiteit Utrecht | 477.500 € |
| Viduet Health B.V. | 284.000 € |
Quelle: https://cordis.europa.eu/project/id/101095480
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der letzte verfügbare Stand wird auf folgender Seite wiedergegeben: London School of Economics and Political Science, London, Großbritannien.
